Unmet Medical Needs and Treatment Preferences for Systemic Treatments in Patients with Moderate to Severe Psoriasis: A Cross-Sectional Survey Study in China
Author(s)
Kuang Y1, Li Y2, Lv C3, Li M4, Zhang Z5, Chen Y6, Chen W7, Wang X8, Ba L8, Zhong Y9, Feldman SR10, Chen X1
1Xiangya Hospital of Central South University, Changsha, Hunan, China, 2The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China, 3Dalian Dermatological Diseases Hospital, Dalian, Liaoning, China, 4Dushu Lake Hospital of Suzhou University, Suzhou, Jiangsu, China, 5The 8th Affiliated Hospital of Zhongshan University, Shenzhen, Guangdong, China, 6Changsha Normin Health Technology Ltd, Changsha, Hunan, China, 7Normin Health Consulting Ltd, Mississauga, ON, Canada, 8Bristol Myers Squibb-China, Shanghai, Shanghai, China, 9Bristol Myers Squibb, Lawrenceville, NJ, USA, 10Wake Forest School of Medicine, Winston-Salem, NC, USA
Presentation Documents
OBJECTIVES: To assess the unmet needs and treatment preferences among Chinese patients with moderate to severe psoriasis (msPsO).
METHODS: 300 msPsO patients previously treated with systemic therapies were surveyed in five Chinese tertiary hospitals. The unmet needs defined as treatment effectiveness, safety, convenience, and challenges were assessed for oral drugs (acitretin, methotrexate, cyclosporine, apremilast) and biologics (adalimumab, infliximab, etanercept, secukinumab, ixekizumab, ustekinumab, guselkumab). Treatment preferences were evaluated by a choice-based conjoint (CBC) questionnaire with seven medication attributes for administration route, frequency, effectiveness, and safety. Descriptive statistics were employed to summarize the data; conjoint simulation analyses were conducted to assess the treatment preference.
RESULTS: Mean age of these patients was 43 years old, 63% were males, and 41% were with severe psoriasis. The treatment persistence of oral drugs and biologics were 2.7-6.2 months and 9.5-17.0 months, respectively. The impacts of treatment side effects were reduced quality of life (38%) for oral drugs and increased expenditure related to managing adverse events (AE) for biologics (29%). The most frequently reported treatment inconveniences included regular lab tests to monitor AE of oral drugs (other than apremilast) (49%) and injection preparation for biologics (27.8%). The primary treatment discontinuation reasons were unsatisfactory effectiveness (77%) for oral drugs and loss of efficacy over time (61%) for biologics. The reported treatment challenges with biologics also contained administration assistance needs from healthcare providers (68%), limited access (47%), injection pain (32%), needle fear (31%), injection preparation (28%), and paradoxical skin reactions (6-21%). When attributes were comparable, oral drugs were preferred over subcutaneous injection drugs for moderate (64% vs. 36%) and severe psoriasis (61% vs. 39%).
CONCLUSIONS: This study highlights the unmet needs of current msPsO treatments for effectiveness, safety, convenience, and challenges in Chinese patients. For treatments with comparable medication attributes, Chinese patients with msPsO prefer oral treatment over injection treatment.
Conference/Value in Health Info
Value in Health, Volume 26, Issue 11, S2 (December 2023)
Code
PCR40
Topic
Patient-Centered Research
Topic Subcategory
Stated Preference & Patient Satisfaction
Disease
Sensory System Disorders (Ear, Eye, Dental, Skin)